You are here: Industry Insights > AD

News List

Pharmaceutical Companies Back to the Blue Ocean of AD in the Wake of Aduhelm's Approval PharmaSources/Yefenghong
July 20, 2021
On June 8, the FDA issued an accelerated approval to Biogen/Eisai's powdered protein antibody Aduhelm (generic name aducanumab) for the treatment of Alzheimer's disease (AD).
FDA grants fast track designation to Eisai-Biogen’s Alzheimer’s therapy Pharmaceutical-Technology
December 27, 2021
The US Food and Drug Administration (FDA) has granted Fast Track designation to Eisai and Biogen’s experimental drug, lecanemab, to treat early Alzheimer’s disease (AD).
COVID-19 Severity Does Not Differ for Patients With Skin Conditions Drugs
December 16, 2021
For patients with psoriasis, vitiligo, atopic dermatitis (AD), and chronic urticaria (CU), COVID-19 severity does not differ, but treatment of COVID-19 may affect the course of skin disease...
Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD contractpharma
July 21, 2021
Eisai Co., Ltd. and Biogen’s lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD), was granted Breakthrough Therapy designation from the FDA.
Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData expresspharma
July 05, 2021
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with six of these being topical formulations.
US grants new patent targeting major neurodegenerative diseases europeanpharmaceuticalreview
July 05, 2021
Alterity Therapeutics have been granted a patent for compounds able to redistribute excess iron in the brain being developed as a treatment for neurodegenerative diseases including Alzheimer’s and Parkinson’s.
BMS exercises option for US licence of Prothena’s Alzheimer’s antibody pharmaceutical-technology
June 28, 2021
Bristol Myers Squibb (BMS) has exercised an option under a neuroscience research and development partnership, to obtain an exclusive US licence to Prothena’s anti-tau antibody, PRX005.
FDA grants breakthrough status to Eisai and Biogen’s Alzheimer’s drug pharmaceutical-technology
June 25, 2021
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eisai and Biogen’s lecanemab (BAN2401) for Alzheimer’s disease (AD) treatment.
Alzheimer’s vaccine shows promise in Phase II trial europeanpharmaceuticalreview
June 17, 2021
Study results show AADvac1, a first-in-man Alzheimer’s disease tau vaccine, is safe and potentially of benefit for patients with mild disease.
First patients dosed with Fasenra in three dermatology trials europeanpharmaceuticalreview
April 26, 2021
With the addition of the new dermatology trials, Fasenra is now being evaluated in nine different indications associated with eosinophilic immune dysfunction.

Previous page 1 2 3 Next page